BioCentury | Oct 20, 2020
Management Tracks

J&J promotes Kumar; plus moves at Krystal, Design, Centogene, Lyndra, Mereo and Neoleukin

Johnson & Johnson (NYSE:JNJ) has promoted Seema Kumar to global head of the Office of Innovation, Global Health and Scientific Engagement from VP of innovation, global health and policy communication. Krystal Biotech Inc. (NASDAQ:KRYS) said...
BioCentury | Feb 8, 2020
Management Tracks

Gottlieb joins Illumina’s board; plus Kiniksa, Frequency, DBV, VectivBio and more

Former FDA Commissioner Scott Gottlieb joined the board of next-generation sequencing company Illumina Inc. (NASDAQ:ILMN). The new role is at least his fourth board appointment since stepping down from the agency last year. Along with...
BioCentury | May 9, 2019
Company News

Management tracks: Akebia, Sangamo, Bicycle

Kidney disease company Akebia Therapeutics Inc. (NASDAQ:AKBA) said SVP and CMO Rita Jain will step down, effective June 17, to pursue other opportunities. She will be succeeded by Steven Burke, who was SVP and CMO...
BioCentury | Apr 6, 2019
Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
BioCentury | Apr 5, 2019
Clinical News

Proteon's vonapanitase misses another Phase III

Proteon said vonapanitase missed the co-primary endpoints in the Phase III PATENCY-2 trial to improve vascular access in chronic kidney disease (CKD) patients undergoing surgery for radiocephalic arteriovenous fistula (AVF) creation for hemodialysis. Compared with...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | May 17, 2017
Clinical News

Proteon's vonapanitase receives breakthrough therapy designation

Proteon Therapeutics Inc. (NASDAQ:PRTO) said FDA granted breakthrough therapy designation to vonapanitase to increase arteriovenous fistula (AVF) secondary patency in patients on or expected to start hemodialysis. The recombinant human elastase is in the Phase...
BioCentury | May 12, 2017
Clinical News

Proteon ups Phase III PATENCY-2 enrollment

Proteon Therapeutics Inc. (NASDAQ:PRTO) will for the second time increase enrollment in the ongoing Phase III PATENCY-2 trial of vonapanitase to treat chronic kidney disease (CKD) to correct a calculation error in the trial’s statistical...
BioCentury | Mar 17, 2017
Clinical News

Vonapanitase: Ph III PATENCY-2 amended

Proteon amended the double-blind, placebo-controlled, North American Phase III PATENCY-2 trial of vonapanitase given immediately after radiocephalic AVF to increase enrollment to 500 patients from 300 and to establish secondary patency and fistula use for...
BioCentury | Jan 6, 2017
Finance

Tiers of disappointment

A bad year for biotech was closed with an even worse 4Q16 as volatility ahead of the U.S. elections and continued concerns around drug pricing held every market cap band in the red despite a...
Items per page:
1 - 10 of 67
BioCentury | Oct 20, 2020
Management Tracks

J&J promotes Kumar; plus moves at Krystal, Design, Centogene, Lyndra, Mereo and Neoleukin

Johnson & Johnson (NYSE:JNJ) has promoted Seema Kumar to global head of the Office of Innovation, Global Health and Scientific Engagement from VP of innovation, global health and policy communication. Krystal Biotech Inc. (NASDAQ:KRYS) said...
BioCentury | Feb 8, 2020
Management Tracks

Gottlieb joins Illumina’s board; plus Kiniksa, Frequency, DBV, VectivBio and more

Former FDA Commissioner Scott Gottlieb joined the board of next-generation sequencing company Illumina Inc. (NASDAQ:ILMN). The new role is at least his fourth board appointment since stepping down from the agency last year. Along with...
BioCentury | May 9, 2019
Company News

Management tracks: Akebia, Sangamo, Bicycle

Kidney disease company Akebia Therapeutics Inc. (NASDAQ:AKBA) said SVP and CMO Rita Jain will step down, effective June 17, to pursue other opportunities. She will be succeeded by Steven Burke, who was SVP and CMO...
BioCentury | Apr 6, 2019
Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
BioCentury | Apr 5, 2019
Clinical News

Proteon's vonapanitase misses another Phase III

Proteon said vonapanitase missed the co-primary endpoints in the Phase III PATENCY-2 trial to improve vascular access in chronic kidney disease (CKD) patients undergoing surgery for radiocephalic arteriovenous fistula (AVF) creation for hemodialysis. Compared with...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | May 17, 2017
Clinical News

Proteon's vonapanitase receives breakthrough therapy designation

Proteon Therapeutics Inc. (NASDAQ:PRTO) said FDA granted breakthrough therapy designation to vonapanitase to increase arteriovenous fistula (AVF) secondary patency in patients on or expected to start hemodialysis. The recombinant human elastase is in the Phase...
BioCentury | May 12, 2017
Clinical News

Proteon ups Phase III PATENCY-2 enrollment

Proteon Therapeutics Inc. (NASDAQ:PRTO) will for the second time increase enrollment in the ongoing Phase III PATENCY-2 trial of vonapanitase to treat chronic kidney disease (CKD) to correct a calculation error in the trial’s statistical...
BioCentury | Mar 17, 2017
Clinical News

Vonapanitase: Ph III PATENCY-2 amended

Proteon amended the double-blind, placebo-controlled, North American Phase III PATENCY-2 trial of vonapanitase given immediately after radiocephalic AVF to increase enrollment to 500 patients from 300 and to establish secondary patency and fistula use for...
BioCentury | Jan 6, 2017
Finance

Tiers of disappointment

A bad year for biotech was closed with an even worse 4Q16 as volatility ahead of the U.S. elections and continued concerns around drug pricing held every market cap band in the red despite a...
Items per page:
1 - 10 of 67